BMS Just Broke the Biggest Barrier in Protein Degradation Medicine
BMS's CELMoD drug mezigdomide just delivered a major Phase 3 win in multiple myeloma, providing the strongest clinical validation yet for the targeted protein degradation drug class. The implications stretch far beyond one company and one cancer.
For years, the pitch for targeted protein degradation went something like this: What if, instead of blocking a disease-causing protein, you could just destroy it?
It's a beautiful idea. Elegant, even. But elegant ideas don't treat patients. Clinical data does. And until very recently, the protein degradation field had a lot of promise and not a lot of late-stage proof.
That just changed.
At ASCO 2026, Bristol Myers Squibb revealed that its CELMoD drug mezigdomide delivered a statistically significant and clinically meaningful improvement in progression-free survival in a Phase 3 trial called SUCCESSOR-2. The drug was tested in patients with relapsed or refractory multiple myeloma, one of the toughest cancers to keep in check long-term. And it didn't just nudge the needle. Early whispers from the meeting suggest the PFS benefit was dramatic enough to earn a late-breaking oral presentation, the highest-profile slot ASCO offers.
This isn't just a win for BMS. It's the strongest clinical validation the entire protein degradation drug class has ever seen.
The Drug That Eats Proteins for Breakfast
Let's back up for a second, because the science here is genuinely cool.
Most cancer drugs work like a key jammed into a lock. They block a protein from doing its job. The protein is still there; it's just stuck. Targeted protein degradation takes a completely different approach. Instead of blocking the protein, it tags it for destruction and lets the cell's own recycling machinery chew it up.
Mezigdomide belongs to a class called CELMoDs (cereblon E3 ligase modulators). Think of cereblon as a bouncer at a nightclub. Normally, it checks IDs and decides which proteins get tossed out of the cell. Mezigdomide slips the bouncer a note with a new name on it: get rid of this one too. The cell's protein-shredding system (the proteasome) does the rest.
The specific targets? Transcription factors called Ikaros and Aiolos (IKZF1 and IKZF3), which multiple myeloma cells depend on to survive. Destroy those, and the cancer loses a critical lifeline.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
If this sounds familiar, it should. The blockbuster drugs lenalidomide (Revlimid) and pomalidomide work through the same basic mechanism. But mezigdomide was engineered to be far more potent at flipping cereblon's switch. It's essentially a next-generation version of a drug class that already generates billions in annual revenue.
What SUCCESSOR-2 Actually Showed
The trial design was straightforward. Patients with relapsed or refractory multiple myeloma who had already been through at least one prior line of treatment were randomized to one of two groups. One group received mezigdomide plus carfilzomib and dexamethasone (the triplet, called MeziKd). The other got carfilzomib and dexamethasone alone (Kd), which is already a standard regimen in this setting.
The primary endpoint was progression-free survival: how long patients lived without their cancer getting worse.
BMS reported in March 2026 that the trial hit its mark. MeziKd showed a statistically significant PFS improvement over the control arm. The company described the benefit as "clinically meaningful," which in pharma-speak usually means the improvement was large enough that doctors, regulators, and payers will all take it seriously.
The exact numbers (median PFS, hazard ratio, confidence intervals) haven't been released publicly yet; those details are expected to come in the full ASCO oral presentation. But the fact that this earned a late-breaking slot tells you the data is striking. ASCO doesn't hand out those invitations for marginal results.
Overall survival data is still maturing, with follow-up ongoing. And importantly, the safety profile looked consistent with what earlier studies had shown for mezigdomide. No scary new signals popped up, which matters enormously when you're adding a drug to an existing backbone.
Why This Is Bigger Than One Drug
To appreciate why the myeloma world is buzzing, you need to understand the competitive landscape. Multiple myeloma treatment has been transformed over the past five years by two flashy new modalities: bispecific antibodies and CAR-T cell therapy. Both have shown jaw-dropping response rates in heavily pretreated patients.
Just look at the MajesTEC-9 data for the bispecific teclistamab, which showed a 71% reduction in the risk of progression or death compared to standard care. That's a tough bar to clear.
So where does an oral pill like mezigdomide fit? Potentially everywhere that bispecifics and CAR-T can't reach. Those therapies require infusions, hospitalization, and careful monitoring for side effects like cytokine release syndrome. They're expensive, logistically complex, and not available at every cancer center. An oral triplet that significantly extends PFS? That's a therapy oncologists can prescribe in their office tomorrow. No specialized centers needed.
And mezigdomide isn't alone. BMS has an entire CELMoD franchise:
Iberdomide already hit its Phase 3 endpoint (MRD negativity) in the EXCALIBER-RRMM trial and is heading toward regulatory discussions. Analysts project $1 to $5 billion in peak sales.
Golcadomide is being developed in lymphoma, with multiple trials open for enrollment.
BMS is building a platform, not just a product. And SUCCESSOR-2 is the proof that the platform works in the most demanding clinical setting: a randomized Phase 3 trial with a hard survival endpoint.
The Signal That Echoes Across Biotech
The protein degradation field has been growing fast. But most programs are early-stage. Phase 1 dose-finding studies. Proof-of-concept work.
What's been missing is a clean Phase 3 win on a major clinical endpoint. That's the gap SUCCESSOR-2 fills.
For the broader field, this sends several important signals:
For other CELMoD developers: C4 Therapeutics has its own IKZF1/3 degrader (CFT-7455) in Phase 1/2 trials for myeloma and lymphoma. Monte Rosa is testing a GSPT1-targeting molecular glue (MRT-2359) in solid tumors. Novartis has DKY-709, a glue that degrades IKZF2 in regulatory T cells, potentially unlocking new immunotherapy combinations. All of these programs just got a little more credible, because the underlying mechanism now has late-stage clinical proof.
For the PROTAC crowd: PROTACs (the other major flavor of protein degraders) have been racing toward approvals too, led by Arvinas' ARV-471 in breast cancer. Mezigdomide's success validates the core concept that recruiting the cell's recycling machinery to destroy disease proteins can produce real clinical benefits. Rising tides, bigger boats.
For investors and dealmakers: Expect the phone lines to light up. Takeda signed an exclusive licensing deal with Degron Therapeutics in 2024 to develop next-gen molecular glues. Kymera partnered with NEOsphere the same year. With Phase 3 validation now in hand, the bidding war for degrader technology is about to intensify.
What Wall Street Is Watching
Analysts had already been modeling mezigdomide as a potential $1.5 billion peak-sales drug, assuming positive Phase 3 data. That assumption just got a lot more concrete.
The key questions heading into the full ASCO presentation are specific and measurable. What's the exact hazard ratio? What does PFS look like in high-risk cytogenetic subgroups? How does MeziKd compare in patients who've already failed anti-CD38 antibodies or BCMA-targeted therapies?
And perhaps most importantly: when will BMS file for approval? The company now has two positive Phase 3 CELMoD readouts (SUCCESSOR-2 for mezigdomide, EXCALIBER-RRMM for iberdomide). Iberdomide is already under FDA priority review. Mezigdomide's regulatory submission could follow quickly, depending on what the full data package looks like.
For BMS specifically, this is about life after Revlimid. The company's legacy immunomodulatory franchise has been bleeding revenue to generic competition. CELMoDs were always supposed to be the next chapter. SUCCESSOR-2 confirms the chapter is worth reading.
The Bottom Line
For a decade, protein degradation has been biotech's favorite "next big thing." Conference slides full of elegant cartoons showing proteins getting tagged and destroyed. Billions of dollars poured into discovery platforms and early-stage trials.
But the question was always the same: can you prove it works where it matters most, in a randomized Phase 3 trial with a survival endpoint?
BMS just answered that question. And the answer echoing through ASCO 2026 is a resounding yes.
The full data presentation at ASCO will fill in the numbers. But the narrative has already shifted. Targeted protein degradation isn't a promising concept anymore. It's a proven drug class. And the race to build the next generation of medicines on this foundation just kicked into a much higher gear.
Clinical & Regulatory5 min read
Big Pharma Is Betting More Than $350 Billion That America Can Make Its Own Drugs Again
Biopharma companies have pledged a jaw-dropping $292 billion to build drug factories in the U.S. since January. But between 100% tariffs, five-year construction timelines, and a severe talent shortage, the gap between promise and production is wider than anyone wants to admit.
